PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3752-3759

  Tesfay, Mulu Z ^a   Kirk, Amber C ^a   Hadac, Elizabeth M ^a   Griesmann, Guy E ^a   Federspiel, Mark J ^a   Barber, Glen N ^b   Henry, Stephen M ^c   Peng, Kah Whye ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; CIRCULATION; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PASSIVE IMMUNIZATION; PEGYLATION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS NEUTRALIZATION;

ANIMALS; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY; DNA PRIMERS; DRUG DISCOVERY; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; MICE; MULTIPLE MYELOMA; NEUTRALIZATION TESTS; ONCOLYTIC VIROTHERAPY; POLYETHYLENE GLYCOLS; REAL-TIME POLYMERASE CHAIN REACTION; VERO CELLS; VESICULAR STOMATITIS INDIANA VIRUS; VIREMIA;

MUS; VESICULAR STOMATITIS VIRUS;

EID: 84875541589     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02832-12     Document Type: Article

References (64)

1. Cook R. 2008. Economic and clinical impact of multiple myeloma to managed care. J. Manag. Care Pharm. 14(7 Suppl):19 -25.
2. Edwards CM, Zhuang J, Mundy GR. 2008. The pathogenesis of the bone disease of multiple myeloma. Bone 42:1007-1013.
3. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. 2007. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. 7:585-598.
4. Kyle RA, Rajkumar SV. 2004. Multiple myeloma. N. Engl. J. Med. 351: 1860-1873.
5. Kyle RA, Rajkumar SV. 2009. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 9:278 -288.
6. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG. 2009. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:2222-2232.
7. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. 2007. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol. Cancer Ther. 6:1701-1708.
8. Cook R. 2008. Introduction: multiple myeloma. J. Manag. Care Pharm. 14(7 Suppl):4-6.
9. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (ed). 2007. SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD.
10. Schwartz RN, Vozniak M. 2008. Current and emerging treatments for multiple myeloma. J. Manag. Care Pharm. 14(7 Suppl):12-19.
11. Chiocca EA. 2008. The host response to cancer virotherapy. Curr. Opin. Mol. Ther. 10:38-45.
12. Kelly E, Russell SJ. 2007. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15:651- 659.
13. Nguyen TL, Tumilasci VF, Singhroy D, Arguello M, Hiscot I. 2009. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell. Microbiol. 11:889-897.
14. Parato KA, Lichty BD, Bell JC. 2009. Diplomatic immunity: turning a foe into an ally. Curr. Opin. Mol. Ther. 11:13-21.
15. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. 2009. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20:1119 -1132.
16. Russell S. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther. 9:961-966.
17. Russell SJ, Peng K-W, Bell JC. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30:658-670.
18. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. 2007. Oncolytic viruses in cancer therapy. Cancer Lett. 254:178 -216.
19. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AP, Bell JC, Russell SJ. 2007. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV (δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110:2342-2350.
20. Liu TC, Galanis E, Kim D. 2007. Clinical trial with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4:101- 117.
21. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. 2012. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26:1870 -1878.
22. Naik S, Nace R, Barber GN, Russell SJ. 2012. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther. 19:443- 450.
23. Stief AE, McCart JA. 2008. Oncolytic virotherapy for multiple myeloma. Expert Opin. Biol. Ther. 8:463- 473. 24. Wagner RR, Rose JK. 1996. Rhabdoviridae: the viruses and their replication, p 1121-1135. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
24. Wagner RR, Rose JK. 1996. Rhabdoviridae: the viruses and their replication, p 1121-1135. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
25. Belkowski LS, Sen GC. 1987. Inhibition of vesicular stomatitis viral mRNA synthesis by interferon. J. Virol. 61:653- 660.
26. Carey BL, Ahmed M, Puckett S, Lyles DS. 2008. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 82:12104 -12115.
27. Obuchi M, Fernandez M, Barber GN. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:8843- 8856.
28. Stojdl DE, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821- 825.
29. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin E, Hiscott J, Bell JC. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
30. Lichty BD, Power AT, Stojdl DF, Bell JC. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210 -216.
31. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC. 2004. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum. Gene Ther. 15:821- 831.
32. Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM. 2010. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-β for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 21:51- 64.
33. Power AT, Bell JC. 2008. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther. 15: 772-779.
34. Ferguson MS, Lemoine NR, Wang Y. 2012. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. 2012:805629. doi:10.1155/2012/805629.
35. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. 2008. Extravasation and homing mechanisms in multiple myeloma. Clin. Exp. Metastasis 25:325-334.
36. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, IV, Louis DN, Bartus RT, Hochberg FH, Chiocca EA. 1999. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5:881- 887.
37. Kueberuwa G, Cawood R, Seymour LW. 2010. Blood compatibility of enveloped viruses. Curr. Opin. Mol. Ther. 12:412- 420.
38. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. 2007. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 14:324 -333.
39. Tedcastle A, Cawood R, Di Y, Fisher KD, Seymour LW. 2012. Virotherapy- cancer targeted pharmacology. Drug Discov. Today 17:215- 220.
40. Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JA, Brunner LJ, Kobinger GP. 2004. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78:912-921.
41. Croyle MA, Yu Q-C, Wilson JM. 2000. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11: 1713-1722.
42. Laga R, Carlisle R, Tangney M, Ulbrich K, Seymour LW. 2012. Polymer coatings for delivery of nucleic acid therapeutics. J. Control. Release 160: 537-553.
43. Liu C, Russell SJ, Peng K-W. 2010. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther. 18:1155-1164.
44. Munguia A, Ota T, Miest T, Russell SJ. 2008. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 15:797- 806.
45. O'Riordan CR, Lachapelle A, Delado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. 1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10:1349 -1358.
46. Alconcel NSS, Baas AS, Maynard HD. 2011. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polymer Chem. 2:1442-1448.
47. Cheng X, Ming X, Croyle MA. 2003. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm. Res. 20: 1444-1451.
48. De Geest B, Snoeys J, Van Linthout S, Lievens J, Collen D. 2005. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 16:1439 -1451.
49. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. 2009. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther. 20:975-988.
50. Eto Y, Yoshioka Y, Ishida T, Yao X, Morishige T, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Kiwada H, Nakagawa S. 2010. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol. Pharm. Bull. 33:1540 -1544.
51. Wonganan P, Clemens CC, Brasky K, Pastore L, Croyle MA. 2011. Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus. Mol. Pharm. 8:78 -92.
52. Beebe DP, Cooper NR. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126:1562-1568.
53. Blake DA, Bovin NV, Bess D, Henry SM. 2011. FSL constructs: a simple method for modifying cell/virion surfaces with a range of biological markers without affecting their viability. J. Vis. Exp. 54:e3289. doi:10.3791/3289.
54. Hadac EM, Federspiel MJ, Chernyy E, Tuzikov A, Korchagina E, Bovin NV, Russell S, Henry SM. 2011. Fluorescein and radiolabeled functionspacer- lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions. J. Virol. Methods 176:78-84.
55. RadlJ CJ, Zurcher C, van den Enden-Vieveen MM, de Leeuw AM. 1988. Animal model of human disease: multiple myeloma. Am. J. Cancer 132: 593-597.
56. Jayasekera JP, Moseman EA, Carroll MC. 2007. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 81:3487-3494.
57. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, Chiocca EA. 2000. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74:4765- 4775.
58. DePolo NJ, Harkleroad CE, Bodner M, Watt AT, Anderson CG, Greengard JS, Murthy KK, Dubensky TW, Jr, Jolly DJ. 1999. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73:6708-6714.
59. Mason JM, Guzowski DE, Goodwin LO, Porti D, Cronin KC, Teichberg S, Pergolizzi RG. 1999. Human serum-resistant retroviral vector particles from galactosyl (α1-3) galactosyl containing nonprimate cell lines. Gene Ther. 6:1397-1405.
60. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK. 1994. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68:8001- 8007.
61. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RAB, Pasternack MS, Chiocca EA. 2002. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5:275-282.
62. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA. 2008. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16:1276 -1282.
63. Carlisle RC, Di Y, Cerny AM, Sonnen AFP, Sim RB, Green NK, Subr V, Ulbrich K, Gilbert RJC, Fisher KD, Finberg RW, Seymour LW. 2009. Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113:1909 -1918.
64. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan- Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD. 2006. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 14:118 -128.